Effects of bevacizumab in mouse model of endometrial cancer: Defining the molecular basis for resistance

Oncology Reports

Volumn 25, Issue 3, 2011, Pages 855-862

  Davies, Suzy ^a   Dai, Donghai ^b   Pickett, Gavin ^a   Thiel, Kristina W ^b   Korovkina, Victoria P ^b   Leslie, Kimberly K ^b  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Bevacizumab; Endometrial cancer; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CD134 ANTIGEN; COLLAGEN TYPE 5; COLLAGEN TYPE 9; COLLAGENASE 3; MATRIX METALLOPEPTIDASE 14; MATRIX METALLOPEPTIDASE 15; MATRIX METALLOPROTEINASE 15; PR DOMAIN CONTAINING PROTEIN 16; PROGRAMMED CELL DEATH 4; PROTEIN; PROTEIN P53; PROTEIN P53 BINDING PROTEIN 1; RHO GTPASE ACTIVATING PROTEIN 6 TRANSCRIPT VARIANT 1; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG SENSITIVITY; ENDOMETRIUM CANCER; HUMAN; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; MICE; MICE, NUDE; TUMOR BURDEN; VALIDATION STUDIES AS TOPIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79551613703     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1147     Document Type: Article

References (49)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer Statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. McCann SE, Freudenheim JL, Marshall JR, Brasure JR, Swanson MK and Graham S: Diet in the epidemiology of endometrial cancer in Western New York (United States). Cancer Causes Control 11: 965-974, 2000.
3. Cancer Facts and Figures 2010. http://www.cancer.org/acs/groups/content/ @nho/documents/document/acspc-024113.pdf. Am Cancer Soc 2010.
4. Kamat AA, Merritt WM, Coffey D, et al: Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 13: 7487-7495, 2007.
5. McMeekin DS, Sill MW, Benbrook D, et al: A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecol Oncol 105: 508-516, 2007. (Pubitemid 46591977)
6. Sanseverino F, Santopietro R, Torricelli M, et al: pRb2/p130 and VEGF expression in endometrial carcinoma in relation to angiogenesis and histopathologic tumor grade. Cancer Biol Ther 5: 84-88, 2006.
7. Hirai M, Nakagawara A, Oosaki T, Hayashi Y, Hirono M and Yoshihara T: Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. Gynecol Oncol 80: 181-188, 2001.
8. Cerezo L, Cardenes H and Michael H: Molecular alterations in the pathogenesis of endometrial adenocarcinoma. Therapeutic implications. Clin Transl Oncol 8: 231-241, 2006.
9. Wright JD, Powell MA, Rader JS, Mutch DG and Gibb RK: Bevacizumab therapy in patients with recurrent uterine neoplasms. Anticancer Res 27: 3525-3528, 2007. (Pubitemid 47607497)
10. Aghajanian C, Sill MW, Darcy K, et al: A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group (GOG) study. J Clin Oncol 27: abs. 5531, 2009.
11. Ortega J, Vigil CE and Chodkiewicz C: Current progress in targeted therapy for colorectal cancer. Cancer Control 17: 7-15, 2010.
12. Koutras AK, Fountzilas G, Makatsoris T, Peroukides S and Kalofonos HP: Bevacizumab in the treatment of breast cancer. Cancer Treat Rev 36: 75-82, 2010.
13. Tamaskar I and Pili R: Update on novel agents in renal cell carcinoma. Expert Rev Anticancer Ther 9: 1817-1827, 2009.
14. Norden AD, Drappatz J and Wen PY: Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 5: 610-620, 2009.
15. Albitar L, Laidler LL, Abdallah R and Leslie KK: Regulation of signaling phosphoproteins by epidermal growth factor and Iressa (ZD1839) in human endometrial cancer cells that model type I and II tumors. Mol Cancer Ther 4: 1891-1899, 2005.
16. Albitar L, Pickett G, Morgan M, Davies S and Leslie KK: Models representing type I and type II human endometrial cancers: Ishikawa H and Hec50co cells. Gynecol Oncol 106: 52-64, 2007. (Pubitemid 46898570)
17. Dai D, Albitar L, Nguyen T, Laidler LL, Singh M and Leslie KK: A therapeutic model for advanced endometrial cancer: systemic progestin in combination with local adenoviral-mediated progesterone receptor expression. Mol Cancer Ther 4: 169-175, 2005.
18. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2[-Delta DeltaC(T)] method. Methods 25: 402-408, 2001.
19. Dai D, Litman ES, Schonteich E and Leslie KK: Progesterone regulation of activating protein-1 transcriptional activity: a possible mechanism of progesterone inhibition of endometrial cancer cell growth. J Steroid Biochem Mol Biol 87: 123-131, 2003. (Pubitemid 37532519)
20. Horn L and Sandler A: Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer. Clin Cancer Res 15: 5040-5048, 2009.
21. Jenab-Wolcott J and Giantonio BJ: Bevacizumab: current indications and future development for management of solid tumors. Expert Opin Biol Ther 9: 507-517, 2009.
22. Aragon-Ching JB and Dahut WL: VEGF inhibitors and prostate cancer therapy. Curr Mol Pharmacol 2: 161-168, 2009.
23. Hotary K, Li X-Y, Allen E, Stevens SL and Weiss SJ: A cancer cell metalloprotease triad regulates the basement membrane transmigration program. Genes Dev 20: 2673-2686, 2006. (Pubitemid 44498378)
24. Xia H, Qi Y, Ng SS, et al: microRNA-146b inhibits glioma cell migration and invasion by targeting MMPs. Brain Res 1269: 158-165, 2009.
25. Prakash SK, Paylor R, Jenna S, et al: Functional analysis of ARHGAP6, a novel GTPase-activating protein for RhoA. Hum Mol Genet 9: 477-488, 2000.
26. Lu Q, Longo FM, Zhou H, Massa SM and Chen YH: Signaling through Rho GTPase pathway as viable drug target. Curr Med Chem 16: 1355-1365, 2009.
27. Dogan T, Harms GS, Hekman M, et al: X-linked and cellular IAPs modulate the stability of C-RAF kinase and cell motility. Nat Cell Biol 10: 1447-1455, 2008.
28. Voisin L, Julien C, Duhamel S, et al: Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors. BMC Cancer 8: 337, 2008.
29. Colomiere M, Ward AC, Riley C, et al: Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer 100: 134-144, 2008.
30. Fromigué O, Hamidouche Z and Marie PJ: Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion. J Biol Chem 283: 30549-30556, 2008.
31. Nieves-Alicea R, Colburn N, Simeone AM and Tari A: Programmed cell death 4 inhibits breast cancer cell invasion by increasing tissue inhibitor of metalloproteinases-2 expression. Breast Cancer Res Treat 114: 203-209, 2009.
32. Goke R, Barth P, Schmidt A, Samans B and Lankat-Buttgereit B: Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21Waf1/Cip1. Am J Physiol Cell Physiol 287: C1541-C1546, 2004.
33. Takahata M, Inoue Y, Tsuda H, et al: SKI and MEL1 cooperate to inhibit transforming growth factor-beta signal in gastric cancer cells. J Biol Chem 284: 3334-3344, 2009.
34. Xinh PT, Tri NK, Nagao H, et al: Breakpoints at 1p36.3 in three MDS/AML(M4) patients with t(1;3)(p36;q21) occur in the first intron and in the 5′ region of MEL1. Genes Chromosomes Cancer 36: 313-317, 2003.
35. Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE and Pagano M: S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 314: 467-471, 2006. (Pubitemid 44628968)
36. Zong W, Meyn LA and Moalli PA: The amount and activity of active matrix metalloproteinase 13 is suppressed by estradiol and progesterone in human pelvic floor fibroblasts. Biol Reprod 80: 367-374, 2009.
37. Stratman AN, Saunders WB, Sacharidou A, et al: Endothelial cell lumen and vascular guidance tunnel formation requires MT1-MMP-dependent proteolysis in 3-dimensional collagen matrices. Blood 114: 237-247, 2009.
38. Devy L, Huang L, Naa L, et al: Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res 69: 1517-1526, 2009.
39. Liu H, Lu ZG, Miki Y and Yoshida K: Protein kinase C delta induces transcription of the TP53 tumor suppressor gene by controlling death-promoting factor Btf in the apoptotic response to DNA damage. Mol Cell Biol 27: 8480-8491, 2007.
40. Lu W, Finnis S, Xiang C, et al: Tyrosine 311 is phosphorylated by c-Abl and promotes the apoptotic effect of PKCdelta in glioma cells. Biochem Biophys Res Commun 352: 431-436, 2007.
41. Reno EM, Haughian JM, Dimitrova IK, Jackson TA, Shroyer KR and Bradford AP: Analysis of protein kinase C delta (PKC delta) expression in endometrial tumors. Hum Pathol 39: 21-29, 2008.
42. Kitamura K, Mizuno K, Etoh A, et al: The second phase activation of protein kinase C delta at late G1 is required for DNA synthesis in serum-induced cell cycle progression. Genes Cells 8: 311-324, 2003.
43. Gliki G, Wheeler-Jones C and Zachary I: Vascular endothelial growth factor induces protein kinase C (PKC)-dependent Akt/PKB activation and phosphatidylinositol 3′-kinase-mediates PKC delta phosphorylation: role of PKC in angiogenesis. Cell Biol Int 26: 751-759, 2002. (Pubitemid 35266492)
44. Toschi A, Lee E, Xu L, Garcia A, Gadir N and Foster DA: Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol Cell Biol 29: 1411-1420, 2009.
45. Koike K, Fujii T, Nakamura AM, et al: Activation of protein kinase C delta induces growth arrest in NPA thyroid cancer cells through extracellular signal-regulated kinase mitogen-activated protein kinase. Thyroid 16: 333-341, 2006.
46. Shi X, Zhang H, Paddon H, Lee G, Cao X and Pelech S: Phosphorylation of STAT3 serine-727 by cyclin-dependent kinase 1 is critical for nocodazole-induced mitotic arrest. Biochemistry 45: 5857-5867, 2006.
47. Lacreusette A, Barbieux I, Nguyen JM, et al: Defective activations of STAT3 Ser727 and PKC isoforms lead to oncostatin M resistance in metastatic melanoma cells. J Path 217: 665-676, 2009.
48. Le Page C, Puiffe ML, Meunier L, et al: BMP-2 signaling in ovarian cancer and its association with poor prognosis. J Ovarian Res 2: 4, 2009.
49. Johnsen IK, Kappler R, Auernhammer CJ and Beuschlein F: Bone morphogenetic proteins 2 and 5 are down-regulated in adrenocortical carcinoma and modulate adrenal cell proliferation and steroidogenesis. Cancer Res 69: 5784-5792, 2009.